Gastrointestinal Neuroendocrine Tumors: Diagnosis Using Gastrin Receptor Scintigraphy

2008 ◽  
pp. 43-52
Author(s):  
Martin Gotthardt ◽  
Thomas M. Behr ◽  
Martin Béhé
Keyword(s):  
Neuroendocrine Tumors ◽  
Gastrin Receptor ◽  
Receptor Scintigraphy

scholarly journals Validation of Somatostatin Receptor Scintigraphy in the Localization of Neuroendocrine Tumors

1993 ◽  
Vol 32 (2) ◽  
pp. 167-170 ◽  
Author(s):  
Steven W. J. Lamberts ◽  
Jean-Claude Reubi ◽  
Eric P. Krenning
Keyword(s):  
Neuroendocrine Tumors ◽  
Somatostatin Receptor ◽  
Somatostatin Receptor Scintigraphy ◽  
Receptor Scintigraphy

scholarly journals 68Ga-DOTA-Tyr3-Octreotide PET in Neuroendocrine Tumors: Comparison with Somatostatin Receptor Scintigraphy and CT

2007 ◽  
Vol 48 (4) ◽  
pp. 508-518 ◽  
Author(s):  
M. Gabriel ◽  
C. Decristoforo ◽  
D. Kendler ◽  
G. Dobrozemsky ◽  
D. Heute ◽  
...  
Keyword(s):  
Neuroendocrine Tumors ◽  
Somatostatin Receptor ◽  
Somatostatin Receptor Scintigraphy ◽  
Receptor Scintigraphy

Improved tumour detection by gastrin receptor scintigraphy in patients with metastasised medullary thyroid carcinoma

2006 ◽  
Vol 33 (11) ◽  
pp. 1273-1279 ◽  
Author(s):  
Martin Gotthardt ◽  
Martin P. Béhé ◽  
Daniela Beuter ◽  
Anke Battmann ◽  
Artur Bauhofer ◽  
...  
Keyword(s):  
Thyroid Carcinoma ◽  
Medullary Thyroid Carcinoma ◽  
Medullary Thyroid ◽  
Tumour Detection ◽  
Gastrin Receptor ◽  
Receptor Scintigraphy

scholarly journals Added value of gastrin receptor scintigraphy in comparison to somatostatin receptor scintigraphy in patients with carcinoids and other neuroendocrine tumours

2006 ◽  
Vol 13 (4) ◽  
pp. 1203-1211 ◽  
Author(s):  
Martin Gotthardt ◽  
Martin P Béhé ◽  
Julia Grass ◽  
Artur Bauhofer ◽  
Anja Rinke ◽  
...  
Keyword(s):  
Neuroendocrine Tumours ◽  
Somatostatin Receptor ◽  
Somatostatin Receptor Scintigraphy ◽  
Added Value ◽  
Imaging Method ◽  
Gastrin Receptor ◽  
Additional Information ◽  
Receptor Scintigraphy ◽  
Better Than

Gastrin receptor scintigraphy (GRS) is a new imaging method primarily developed for the detection of metastases of medullary thyroid carcinoma (MTC). As gastrin-binding CCK2 receptors are also expressed on a variety of other neuroendocrine tumours (NET), we compared GRS to somatostatin receptor scintigraphy (SRS) in patients with NET. SRS and GRS were performed within 21 days in a series of 60 consecutive patients with NET. GRS was directly compared with SRS. If lesions were visible on GRS but not detectable by SRS, other imaging modalities (MRI, CT) and follow-up were used for verification. Of the 60 evaluable patients, 51 had carcinoid tumours, 3 gastrinomas, 2 glucagonomas, 1 insulinoma and 3 paragangliomas. The overall tumour-detection rate was 73.7% for GRS and 82.1% for SRS. In the 11 patients with negative SRS, GRS was positive in 6 (54.5%). Based on the number of tumour sites detected and the degree of uptake, GRS performed better than SRS in 13 patients (21.7%), equivalent images were obtained in 18 cases (30.0%) and SRS performed better in 24 (40.0%) cases. In six of the SRS positive patients, 18 additional sites of tumour involvement could be detected. Overall, GRS detected additional tumour sites in 20% of the patients. Localisation of the primary tumours or their functional status had no influence on the outcome of imaging. GRS should be performed in selected patients as it may provide additional information in patients with NET with equivocal or absent somatostatin uptake.

Sign in / Sign up

Export Citation Format

Share Document